Show simple item record

dc.contributor.authorGarriock, Holly
dc.contributor.authorDelgado, Pedro
dc.contributor.authorKling, Mitchel
dc.contributor.authorCarpenter, Linda
dc.contributor.authorBurke, Michael
dc.contributor.authorBurke, William
dc.contributor.authorSchwartz, Thomas
dc.contributor.authorMarangell, Lauren
dc.contributor.authorHusain, Mustafa
dc.contributor.authorErickson, Robert
dc.contributor.authorMoreno, Francisco
dc.date.accessioned2016-05-20T08:56:24Z
dc.date.available2016-05-20T08:56:24Z
dc.date.issued2006en
dc.identifier.citationBehavioral and Brain Functions 2006, 2:24 doi:10.1186/1744-9081-2-24en
dc.identifier.doi10.1186/1744-9081-2-24en
dc.identifier.urihttp://hdl.handle.net/10150/610010
dc.description.abstractBACKGROUND:The objective of the study was to determine the genetic basis of Major Depressive Disorder, and the capacity to respond to antidepressant treatment. An association study of 21 candidate polymorphisms relevant to monoamine function and the mechanism of antidepressant response was conducted in 3 phenotypically distinct samples: a group with chronic or recurrent depression unable to respond to antidepressants (non-responders) (n = 58), a group capable of symptomatic improvement with or without treatment (responders) (n = 39), and volunteer controls (n = 85). The responders and non-responders constituted a larger group of depressed subjects.METHODS:A candidate gene approach was employed to asses the genetics basis of Major Depressive Disorder. The genotypic frequencies of selected polymorphisms were compared between the controls and depressed subjects. To asses the genetics basis of the capacity to respond to antidepressant treatment, the responders were compared to the non-responders. Candidate genes were chosen based on functional studies and proximity to whole genome linkage findings in the literature. Risk genotypes were identified by previous functional studies and association studies.RESULTS:A statistically significant difference in genotype frequency for the SLC6A4 intron 2 VNTR was detected between the subjects with a history of depression and controls (p = 0.004). Surprisingly, a statistically significant difference was detected between responders and non-responders for the DRD4 exon III VNTR genotype frequencies (p = 0.009). Furthermore, a difference between the controls and depressed subjects as well as between the controls and non-responders was detected for the number and distribution of risk genotypes in each group.CONCLUSION:An association between several monoamine-related genes and Major Depressive Disorder is supported. The data suggest that the two depressive phenotypes are genetically different, inferring that the genetic basis for the capacity to respond to standard antidepressant treatment, and the genetic susceptibility to Major Depressive Disorder may be independent. In addition, a proof of concept is provided demonstrating that the number of risk genotypes may be an indication of susceptibility of major depressive disorder and the severity of the disorder.
dc.language.isoenen
dc.publisherBioMed Centralen
dc.relation.urlhttp://www.behavioralandbrainfunctions.com/content/2/1/24en
dc.rights© 2006 Garriock et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).en
dc.rights.urihttps://creativecommons.org/licenses/by/2.0/
dc.titleNumber of risk genotypes is a risk factor for major depressive disorder: a case control studyen
dc.typeArticleen
dc.identifier.eissn1744-9081en
dc.contributor.departmentInterdisciplinary Program in Genetics, Department of Psychiatry, University of Arizona, Tucson, AZ, USAen
dc.contributor.departmentDepartment of Psychiatry, College of Medicine, The University of Arizona Health Sciences Center, 1501 N. Campbell Ave. 7-OPC, Tucson, Arizona 85724, Phone (520) 626-6509, Fax (520) 626-6050, USAen
dc.contributor.departmentDepartment of Psychiatry, University of Texas Health Sciences Center at San Antonio, San Antonio, TX, USAen
dc.contributor.departmentNeuroscience Center, National Institute of Mental Health, Rockville, MD, USAen
dc.contributor.departmentDepartment of Psychiatry, Butler Hospital Brown University, Providence, RI, USAen
dc.contributor.departmentDepartment of Psychiatry and Behavioral Sciences, Kansas University School of Medicine, Witchita, KS, USAen
dc.contributor.departmentDepartment of Psychiatry, University of Nebraska Medical Center, Omaha, NE, USAen
dc.contributor.departmentDepartment of Psychiatry, New York State School of Medicine, Purchase, NY, USAen
dc.contributor.departmentDepartment of Psychiatry, Baylor College of Medicine, Waco, TX, USAen
dc.contributor.departmentDepartment of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USAen
dc.contributor.departmentDepartments of Pediatrics and Molecular & Cellular Biology, University of Arizona, Tucson, AZ, USAen
dc.identifier.journalBehavioral and Brain Functionsen
dc.description.collectioninformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at repository@u.library.arizona.edu.en
dc.eprint.versionFinal published versionen
refterms.dateFOA2018-06-30T17:09:52Z
html.description.abstractBACKGROUND:The objective of the study was to determine the genetic basis of Major Depressive Disorder, and the capacity to respond to antidepressant treatment. An association study of 21 candidate polymorphisms relevant to monoamine function and the mechanism of antidepressant response was conducted in 3 phenotypically distinct samples: a group with chronic or recurrent depression unable to respond to antidepressants (non-responders) (n = 58), a group capable of symptomatic improvement with or without treatment (responders) (n = 39), and volunteer controls (n = 85). The responders and non-responders constituted a larger group of depressed subjects.METHODS:A candidate gene approach was employed to asses the genetics basis of Major Depressive Disorder. The genotypic frequencies of selected polymorphisms were compared between the controls and depressed subjects. To asses the genetics basis of the capacity to respond to antidepressant treatment, the responders were compared to the non-responders. Candidate genes were chosen based on functional studies and proximity to whole genome linkage findings in the literature. Risk genotypes were identified by previous functional studies and association studies.RESULTS:A statistically significant difference in genotype frequency for the SLC6A4 intron 2 VNTR was detected between the subjects with a history of depression and controls (p = 0.004). Surprisingly, a statistically significant difference was detected between responders and non-responders for the DRD4 exon III VNTR genotype frequencies (p = 0.009). Furthermore, a difference between the controls and depressed subjects as well as between the controls and non-responders was detected for the number and distribution of risk genotypes in each group.CONCLUSION:An association between several monoamine-related genes and Major Depressive Disorder is supported. The data suggest that the two depressive phenotypes are genetically different, inferring that the genetic basis for the capacity to respond to standard antidepressant treatment, and the genetic susceptibility to Major Depressive Disorder may be independent. In addition, a proof of concept is provided demonstrating that the number of risk genotypes may be an indication of susceptibility of major depressive disorder and the severity of the disorder.


Files in this item

Thumbnail
Name:
1744-9081-2-24.pdf
Size:
273.8Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record

© 2006 Garriock et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).
Except where otherwise noted, this item's license is described as © 2006 Garriock et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0).